Why I'm I doing This?
I'm Carey and I want to do more. I am riding my bike on June 10 for 50 miles in the hilly area of Hudson, NY? This won't be easy, but neither is finding a cure for Cancer.
3 years ago, I was asked to do a bike ride across Maine (west to east) that took me 3 days. My first reaction was "hell no". After a lot of support from friends that were riding I reluctantly said yes. Each day was about 60 miles, average. It was a fundraiser for Cancer and a team building adventure. I raised my goal and I rode the miles. The ride was brutal for me but I finished with support of friends who had made the ride before. It was cold and rainy for most of the three days and I got achilles tendinitis in both legs. At the end of the ride I barely could walk. It took me over 8 weeks to recover.
People with cancer go thru much worse than that and survive, but only a few. I want to do what I can do to raise awareness and support for something bigger than me. And I too have family members that have been effected by Cancer. Some survived and some didn't. Sitting on the sidelines has never been a part of who I am, so I participate in life and show up when I can.
I am asking my friends, family, and colleagues to support me in whatever way they can to help me reach my goal of $1,000 before my ride on June 9th. Give what you can from $5, $10, $50, $100, $500. Any support helps. With all this in mind, I have started using these words. Go BIG.
My team is Midnightson Designs!
Frequently Asked Questions
So Who is the Cancer Research Institute?
The Cancer Research Institute (CRI) is the world’s leading nonprofit organization dedicated exclusively to
harnessing the immune system’s power to conquer all cancers. Since 1953, CRI has invested more than
$340 million in research grants and fellowships to support scientists at leading research universities and
clinics around the world. Every day, our scientists are discovering new ways to use immunotherapy in the
treatment of cancer.
Immunotherapy offers an answer to cancer for some patients. It represents the most promising new
cancer treatment approach since the development of the first chemotherapies in the late 1940s. By
harnessing and enhancing the innate powers of the immune system to fight all cancers, immunotherapy
is able to adapt and keep pace with cancer, becoming a “living drug” that may continue to work for
patients long after treatment has ceased. Immunotherapy has been shown to benefit patients with
melanoma, lung cancer, kidney cancer, colorectal cancer, and many other kinds of cancer.
Answer to Cancer (A2C) is a grassroots, community movement to raise awareness and funds for cancer
immunotherapy research. Cyclists, runners, and walkers gather each June in support of CRI’s mission to
find cures to all cancers with immunotherapy.
COUNTDOWN TO RIDE
WHERE THE MONEY GOES
Your generous contributions enable the doctors and scientists to advance immunotherapy and improve
its many benefits for cancer patients.
Improving Immunotherapy Now
Our scientists’ research to better understand current immunotherapies are helping doctors tailor these approaches to improve patient outcomes while protecting them from potentially damaging side effects.
Clinical Trial Opportunities
CRI-supported clinical trials are currently evaluating multiple immunotherapy strategies for patients with the following cancers: skin, ovarian, cervical, breast, colorectal, kidney, brain, lymphoma, myeloma, head and neck, bladder, and prostate. Meanwhile, our Clinical Trial Finder helps connect patients with even more valuable opportunities in immunotherapy clinical trials.
New Tools & Techniques
Innovative technologies designed by our researchers are allowing for non-invasive patient diagnostics, better ways to deliver immunotherapy treatments to patients, and customized models to advance immunotherapy and expand its benefits.
Personalized & Patient-Specific Approaches
Our doctors are developing a way to provide individual patients with the vaccines that are best for them, which has the potential to change how we treat cancer. Other promising avenues being explored include taking advantage of biomarkers ―that could enable easier and earlier detection, smarter treatment decisions, and enhanced patient monitoring.
Innovations in Information Sharing
Our CRI iATLAS is making the National Cancer Moonshot’s Blue Ribbon Panel recommendation into reality. This online database will provide immunological data from 10,000 tumors across 33 cancer types and will catalyze new immunotherapy research and development to benefit even more patients.
Tackling Rare Cancers
Through a new fellowship program, we’re supporting four scientists who are researching a rare form of liver cancer that affects young people with the goal to increase treatment options available to these patients.